Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 32243945.
- Also identified by DOI 10.1016/j.chest.2020.03.039 and PMC identifier 7195335.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.
Medical subject headings
- Antiviral Agents
- Coronavirus Infections
- Critical Illness
- Pandemics
- Pneumonia, Viral
- Pregnancy Complications, Infectious